Get the Stockscreener App
5.32
4.15%
-0.22
Helus Pharma Inc stock is traded at $5.32, with a volume of 486.49K.
It is down -4.15% in the last 24 hours and up +1.14% over the past month.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
See More
Previous Close:
$5.54
Open:
$5.37
24h Volume:
486.49K
Relative Volume:
0.43
Market Cap:
$265.44M
Revenue:
-
Net Income/Loss:
$-122.31M
P/E Ratio:
-1.1783
EPS:
-4.5151
Net Cash Flow:
$-110.41M
1W Performance:
+0.00%
1M Performance:
+1.14%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.20
$5.47
1-Week Range:
$5.05
$5.55
52-Week Range:
$4.29
$8.5498
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
5.32 | 276.41M | 0 | -122.31M | -110.41M | -4.5151 |
VRTX
Vertex Pharmaceuticals Inc
|
426.44 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
711.31 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.00 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.95 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.66 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | TD Cowen | Buy |
| Feb-02-26 | Initiated | Jefferies | Buy |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Stock (HELP) Latest News
symbol__ Stock Quote Price and Forecast - CNN
Helus Pharma Partners With TARA Mind to Boost Phase 3 Depression Trial in Veterans After U.S. Executive Order - TipRanks
Helus Pharma (Nasdaq: HELP) partners with TARA Mind to boost veteran trial access - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Jefferies reiterates Helus Pharma stock rating on anxiety data - Investing.com
Cybin Inc. will Change its Name to Helus Pharma - marketscreener.com
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - The Manila Times
Helus turns to TARA Mind to reach veterans for depression trial - Stock Titan
Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference - TipRanks
Helus Pharma (CYBN) interim CEO to join Milken Global Conference health innovation panel - Stock Titan
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference - The Manila Times
Helus Pharma Partners With TARA Mind to Boost Phase 3 Trial Recruitment for Major Depressive Disorder in Veterans - citybuzz -
Helus Pharma Aligns With U.S. Veteran Mental Health Push in New TARA Mind Partnership - TipRanks
Cybin (CYBN) Helus Pharma joins TARA Mind to boost HLP003 Phase 3 veteran trial - Stock Titan
Helus Pharma partners with TARA Mind for trial recruitment By Investing.com - Investing.com South Africa
Helus Pharma partners with TARA Mind for trial recruitment - Investing.com
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - ChartMill
HELP | Cybin Inc. Common Stock Insider Trading - Quiver Quantitative
Helus Pharma propels therapeutic innovation in mental health and commences trading on Nasdaq - MSN
Helus Pharma CEO Michael Cola steps down; Eric So takes interim CEO role - MSN
Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk? - Yahoo Finance
Helus Pharma Inc. (HELP) News, Articles, Events & Latest Updates - Stocktwits
Chutes & Ladders—Helus shuffles out CEO after two months, adds experience to science board - Fierce Biotech
Helus Pharma adds Langer, Brannan to scientific advisory board By Investing.com - Investing.com India
Helus Pharma Adds Langer and Brannan to Advisory Board to Bolster Late-Stage Mental Health Pipeline - TipRanks
Helus Pharma (Nasdaq: HELP) adds Langer and Brannan to scientific board - Stock Titan
Helus Pharma adds Langer, Brannan to scientific advisory board - Investing.com
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan - The Manila Times
How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative - simplywall.st
Trump's Executive Order May Boost Psychedelic Stocks. Here Are 7 to Buy in 2026 - U.S. News Money
Helus Pharma CEO Michael Cola steps down at board’s request By Investing.com - Investing.com India
Helus Pharma Backs U.S. Executive Order Accelerating Psychedelic Treatment Pathways - TipRanks
Helus Pharma (Nasdaq: CYBN) aligns late-stage NSA pipeline with U.S. psychedelic policy push - Stock Titan
Helus Pharma (CYBN) CEO steps down as co-founder Eric So becomes interim chief - Stock Titan
Psychedelic Stocks Surge After Executive Order, Focus on Compass Pathways (CMPS) - GuruFocus
Helus Pharma Brd Starts Process to Find Permanent CEO >HELP - Moomoo
Helus Pharma CEO Michael Cola steps down at board’s request - Investing.com
Helus Pharma Says Eric So To Resume Role As Interim Chief Executive Officer - TradingView
Helus Pharma welcomes White House order on psychedelic therapies By Investing.com - Investing.com UK
Helus Pharma Inc Stock (HELP) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.78%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):